[
    {
        "pregunta": "1. What poor prognostic factors indicate severe PsA disease?",
        "respuesta": "Poor prognostic factors indicating severe psoriatic arthritis (PsA) include:\n\n- Extensive joint involvement, especially polyarticular disease  \n- Early joint damage or erosions visible on imaging  \n- Elevated inflammatory markers (e.g., ESR, CRP)  \n- Presence of dactylitis (sausage digits) and enthesitis  \n- High disease activity and persistent inflammation despite treatment  \n- Nail dystrophy or severe skin involvement  \n- Genetic factors such as HLA-B27 positivity  \n- Functional impairment or disability early in the disease course  \n\nThese factors suggest aggressive disease requiring close monitoring and potentially more intensive therapy."
    },
    {
        "pregunta": "2. How should treatment decisions be approached given the conditional nature of many recommendations?",
        "respuesta": "Treatment decisions should be approached by carefully considering the specific context, patient preferences, values, and clinical circumstances, since conditional recommendations imply that the best choice may vary depending on these factors. Shared decision-making between clinicians and patients is essential, weighing the benefits, risks, and uncertainties to tailor the treatment plan appropriately."
    },
    {
        "pregunta": "3. How does long-term damage, such as joint deformities or vision loss, influence treatment decisions in psoriatic arthritis?",
        "respuesta": "Long-term damage in psoriatic arthritis, such as joint deformities or vision loss, significantly influences treatment decisions by prompting more aggressive and early intervention to prevent further irreversible damage. Clinicians may prioritize the use of disease-modifying antirheumatic drugs (DMARDs), including biologics or targeted synthetic agents, to control inflammation and halt disease progression. Additionally, treatment plans may include multidisciplinary approaches involving rheumatologists, ophthalmologists, and physical therapists to manage complications and preserve function. Early detection and management are key to minimizing long-term disability and improving quality of life."
    },
    {
        "pregunta": "4. What are the poor prognostic factors that help define severe psoriatic arthritis?",
        "respuesta": "Poor prognostic factors in psoriatic arthritis that help define severe disease include:\n\n- Early onset of disease\n- High number of swollen and tender joints\n- Presence of radiographic joint damage or erosions at baseline\n- Elevated inflammatory markers (e.g., ESR, CRP)\n- Presence of dactylitis (sausage digits)\n- Axial involvement (spine or sacroiliac joints)\n- Nail dystrophy or severe skin involvement\n- Functional impairment or disability early in the disease course\n\nThese factors are associated with more aggressive disease, greater joint damage, and poorer long-term outcomes."
    },
    {
        "pregunta": "5. What is the recommended treatment strategy for PsA patients with predominant enthesitis who are both OSM- and biologic-naive?",
        "respuesta": "For Psoriatic Arthritis (PsA) patients with predominant enthesitis who are both oral small molecule (OSM)- and biologic-naive, the recommended initial treatment typically involves starting with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate, although their efficacy specifically for enthesitis may be limited. If there is inadequate response, escalation to biologic therapies—particularly tumor necrosis factor inhibitors (TNFi) or interleukin-17 inhibitors (IL-17i), which have demonstrated efficacy in enthesitis—is advised. Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used adjunctively for symptom relief. Treatment should be individualized based on disease severity and patient factors."
    },
    {
        "pregunta": "6. How is active psoriatic arthritis (PsA) defined according to the clinical guideline?",
        "respuesta": "Active psoriatic arthritis (PsA) is typically defined in clinical guidelines by the presence of clinical signs of ongoing inflammation, such as tender and swollen joints, enthesitis, or dactylitis, along with elevated inflammatory markers (e.g., ESR or CRP) and active skin psoriasis. The exact criteria may vary, but generally, active PsA refers to patients exhibiting measurable disease activity that warrants initiation or adjustment of therapy."
    },
    {
        "pregunta": "7. Qual é a utilidade do índice PASI na avaliação da gravidade da psoríase em pacientes com PsA?",
        "respuesta": "O índice PASI (Psoriasis Area and Severity Index) é utilizado para avaliar a gravidade e a extensão da psoríase em pacientes, incluindo aqueles com artrite psoriásica (PsA). Ele quantifica a área afetada e a intensidade das lesões em termos de eritema, espessura e descamação, auxiliando no monitoramento da resposta ao tratamento e na tomada de decisões clínicas."
    },
    {
        "pregunta": "8. Why are all recommendations regarding switching biologics in active PsA considered conditional and based on very-low-quality evidence?",
        "respuesta": "All recommendations regarding switching biologics in active psoriatic arthritis (PsA) are considered conditional and based on very-low-quality evidence because there is a lack of high-quality, direct comparative studies and randomized controlled trials evaluating the effectiveness and safety of different biologics specifically for switching strategies. Most available data come from observational studies, indirect comparisons, or extrapolations from other conditions, leading to uncertainty about the optimal sequencing of biologic therapies in active PsA."
    },
    {
        "pregunta": "9. Which oral small molecules are considered in PsA treatment guidelines, and how is tofacitinib categorized differently?",
        "respuesta": "Oral small molecules considered in psoriatic arthritis (PsA) treatment guidelines typically include apremilast and Janus kinase (JAK) inhibitors such as tofacitinib. Apremilast is categorized as a phosphodiesterase 4 (PDE4) inhibitor and is often considered a targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Tofacitinib, also a tsDMARD, is specifically a JAK inhibitor and is generally categorized separately due to its distinct mechanism of action and safety profile. Guidelines may position tofacitinib differently, often recommending it after failure of conventional synthetic DMARDs or biologics, reflecting its unique classification among oral small molecules in PsA treatment."
    },
    {
        "pregunta": "10. Quais manifestações extraarticulares podem estar associadas à artrite psoriásica ativa?",
        "respuesta": "As manifestações extraarticulares associadas à artrite psoriásica ativa podem incluir:\n\n- Lesões cutâneas e ungueais típicas da psoríase (placas, escamas, onicólise)\n- Uveíte (inflamação ocular)\n- Síndrome metabólica (obesidade, hipertensão, dislipidemia)\n- Doença inflamatória intestinal (em alguns casos)\n- Alterações pulmonares (fibrose, bronquiolite)\n- Osteoporose e fadiga crônica\n\nEssas manifestações refletem a natureza sistêmica da doença, que pode afetar diversos órgãos além das articulações."
    },
    {
        "pregunta": "11. Describe the typical patterns of peripheral arthritis distribution seen in PsA.",
        "respuesta": "In psoriatic arthritis (PsA), peripheral arthritis typically presents with an asymmetric oligoarticular pattern, often involving a few joints on one side of the body. Commonly affected joints include the distal interphalangeal (DIP) joints, which helps distinguish PsA from rheumatoid arthritis. Other patterns include symmetric polyarthritis resembling rheumatoid arthritis, and arthritis mutilans, which is a severe, deforming form. Additionally, PsA often involves the small joints of the hands and feet, and may affect larger joints such as knees and ankles. Dactylitis (\"sausage digits\") and enthesitis are also characteristic features."
    },
    {
        "pregunta": "12. Quais são alguns exemplos de fatores prognósticos ruins na artrite psoriásica?",
        "respuesta": "Alguns exemplos de fatores prognósticos ruins na artrite psoriásica incluem: presença de lesões articulares erosivas na imagem, envolvimento de múltiplas articulações, presença de dactilite, elevação persistente de marcadores inflamatórios (como PCR e VHS), envolvimento axial, início precoce da doença com sintomas graves, e resposta inadequada ao tratamento inicial. Esses fatores estão associados a maior progressão da doença e pior funcionalidade."
    },
    {
        "pregunta": "13. What biologic therapies are recommended for active PsA patients with concomitant active inflammatory bowel disease (IBD)?",
        "respuesta": "For active psoriatic arthritis (PsA) patients with concomitant active inflammatory bowel disease (IBD), biologic therapies recommended include tumor necrosis factor inhibitors (TNFi) such as infliximab and adalimumab, as these agents are effective for both PsA and IBD. Additionally, ustekinumab, an IL-12/23 inhibitor, is also approved for both conditions and can be considered. Conversely, IL-17 inhibitors are generally avoided in patients with active IBD due to potential exacerbation of bowel disease."
    },
    {
        "pregunta": "14. ¿Qué criterios se utilizan para decidir el cambio de tratamiento en pacientes con PsA activa a pesar del tratamiento con un OSM?",
        "respuesta": "Para decidir el cambio de tratamiento en pacientes con Artritis Psoriásica (PsA) activa a pesar del tratamiento con un fármaco modificador de la enfermedad (OSM), se utilizan los siguientes criterios principales:\n\n1. **Persistencia de actividad inflamatoria**: Evidencia clínica de inflamación activa, como artritis persistente, entesitis, dactilitis o afectación axial, a pesar del tratamiento.\n\n2. **Evaluación de la respuesta terapéutica**: Uso de herramientas clínicas y puntuaciones específicas (por ejemplo, DAS28, PASDAS, o criterios de respuesta ACR) que muestran falta de mejoría o progresión de la enfermedad.\n\n3. **Progresión radiológica**: Signos de daño estructural progresivo en imágenes, como erosiones o pérdida ósea, a pesar del tratamiento.\n\n4. **Impacto en la calidad de vida y funcionalidad**: Persistencia de síntomas que afectan la función y la calidad de vida del paciente.\n\n5. **Tolerancia y efectos secundarios**: Intolerancia o efectos adversos al OSM actual que limitan su uso.\n\nCuando se cumplen estos criterios, se considera cambiar o intensificar el tratamiento, ya sea con otro OSM, terapia biológica o terapias dirigidas, según la evaluación clínica y las guías vigentes."
    },
    {
        "pregunta": "15. Em quais situações pode-se considerar a troca de um TNFi por um inibidor de IL-17 (IL-17i)?",
        "respuesta": "A troca de um TNFi (inibidor do fator de necrose tumoral) por um inibidor de IL-17 (IL-17i) pode ser considerada principalmente nas seguintes situações:\n\n1. Falha primária ou secundária ao TNFi, ou seja, quando o paciente não responde adequadamente ou perde a resposta ao tratamento com TNFi.\n2. Intolerância ou efeitos colaterais significativos relacionados ao uso do TNFi.\n3. Presença de manifestações clínicas específicas, como psoríase cutânea moderada a grave, que podem responder melhor aos IL-17i.\n4. Contraindicações para o uso de TNFi, como certas infecções ou condições clínicas específicas.\n\nEssa troca deve ser avaliada pelo médico com base no perfil clínico do paciente, na resposta ao tratamento anterior e nas características da doença."
    },
    {
        "pregunta": "16. Quais são as recomendações para a transição entre diferentes classes de biológicos em pacientes com resposta parcial ou falha primária ao tratamento atual?",
        "respuesta": "As recomendações para a transição entre diferentes classes de medicamentos biológicos em pacientes com resposta parcial ou falha primária ao tratamento atual incluem:\n\n1. **Avaliação clínica detalhada**: Confirmar a falha terapêutica, considerando adesão, dosagem adequada e duração do tratamento.\n2. **Mudança para outra classe terapêutica**: Em caso de falha primária (ausência de resposta desde o início), recomenda-se trocar para um biológico com mecanismo de ação diferente, para aumentar as chances de resposta.\n3. **Monitoramento contínuo**: Após a troca, acompanhar a resposta clínica e efeitos adversos para ajustar a terapia conforme necessário.\n4. **Consideração de fatores individuais**: Escolha do novo biológico deve levar em conta comorbidades, perfil de segurança, preferências do paciente e custos.\n\nEssas orientações visam otimizar o controle da doença e minimizar riscos."
    },
    {
        "pregunta": "17. For patients with active PsA and predominant enthesitis who are treatment-naive, what is the initial recommended therapy?",
        "respuesta": "For treatment-naive patients with active psoriatic arthritis (PsA) and predominant enthesitis, the initial recommended therapy is typically nonsteroidal anti-inflammatory drugs (NSAIDs). If symptoms persist or are severe, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate may be considered. In cases where there is inadequate response to NSAIDs or csDMARDs, biologic agents targeting tumor necrosis factor (TNF) or interleukin pathways may be initiated."
    },
    {
        "pregunta": "18. Why is etanercept not recommended as a first-line TNFi biologic in PsA patients with active IBD?",
        "respuesta": "Etanercept is not recommended as a first-line TNFi biologic in psoriatic arthritis (PsA) patients with active inflammatory bowel disease (IBD) because it has demonstrated limited efficacy in treating IBD and may not adequately control intestinal inflammation. Unlike monoclonal antibody TNF inhibitors (such as infliximab or adalimumab), etanercept does not consistently improve IBD symptoms and may even be associated with new-onset or worsening of IBD. Therefore, other TNFi agents are preferred in PsA patients with concurrent active IBD."
    },
    {
        "pregunta": "19. What clinical features are included in the assessment of PsA severity?",
        "respuesta": "The assessment of Psoriatic Arthritis (PsA) severity typically includes the evaluation of the following clinical features:\n\n1. **Peripheral arthritis:** Number and pattern of swollen and tender joints.\n2. **Enthesitis:** Presence of inflammation at tendon or ligament insertion sites.\n3. **Dactylitis:** Diffuse swelling of entire digits (\"sausage digits\").\n4. **Axial involvement:** Inflammation of the spine and sacroiliac joints.\n5. **Skin and nail disease:** Extent and severity of psoriasis plaques and nail changes.\n6. **Functional status:** Impact on daily activities and physical function.\n7. **Patient-reported outcomes:** Pain, stiffness, fatigue, and quality of life measures.\n8. **Radiographic damage:** Evidence of joint erosion or new bone formation.\n\nThese features help guide treatment decisions and monitor disease progression."
    },
    {
        "pregunta": "20. Under what circumstances might switching from an IL-17 inhibitor to an IL-12/23 inhibitor be considered instead of switching to a TNF inhibitor?",
        "respuesta": "Switching from an IL-17 inhibitor to an IL-12/23 inhibitor instead of a TNF inhibitor might be considered in cases where a patient with psoriasis or psoriatic arthritis has an inadequate response or intolerance to IL-17 inhibitors and has contraindications to TNF inhibitors, such as a history of demyelinating disease, heart failure, or certain infections. Additionally, IL-12/23 inhibitors may be preferred if the patient's disease phenotype or comorbidities suggest better efficacy or safety with this class."
    }
]